top of page
Join date: Jan 4, 2020
Apr 20, 2023 ∙ 3 min
BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a Phase 2 ready...
Feb 1, 2023 ∙ 1 min
The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist
In December 2022, GSK entered into an exclusive license agreement with biopharma company Zhimeng for CB06-036, a TLR8 agonist. Subject to...
bottom of page